{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T09:47:43Z","timestamp":1768729663110,"version":"3.49.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.beha.2025.101628","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T17:27:23Z","timestamp":1746725243000},"page":"101628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cytokines and immune effector cell therapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Alexandra","family":"Haugh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.beha.2025.101628_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101285","article-title":"TCR gene-engineered cell therapy for solid tumors","volume":"34","author":"Tan","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"3","key":"10.1016\/j.beha.2025.101628_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41571-023-00848-w","article-title":"Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma","volume":"21","author":"Klobuch","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2025.101628_bib3","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.beha.2025.101628_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.beha.2025.101628_bib5","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jcyt.2017.03.067","article-title":"Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion","volume":"19","author":"Kaartinen","year":"2017","journal-title":"Cytotherapy"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101628_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood-2024-204264","article-title":"Rapcabtagene autoleucel (YTB323) in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL): phase II trial clinical update","volume":"144","author":"Riedell","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101628_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.747324","article-title":"Interleukin-7 biology and its effects on immune cells: mediator of generation, differentiation, survival, and homeostasis","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.beha.2025.101628_bib8","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.beha.2025.101628_bib9","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1158\/0008-5472.CAN-10-3843","article-title":"Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies","volume":"71","author":"Singh","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2025.101628_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.675179","article-title":"IL-21 optimizes the CAR-T cell preparation through improving lentivirus mediated transfection efficiency of T cells and enhancing CAR-T cell cytotoxic activities","volume":"8","author":"Du","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"11","key":"10.1016\/j.beha.2025.101628_bib11","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1182\/blood-2007-09-113050","article-title":"IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy","volume":"111","author":"Hinrichs","year":"2008","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.beha.2025.101628_bib12","doi-asserted-by":"crossref","first-page":"82354","DOI":"10.18632\/oncotarget.10510","article-title":"Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","article-title":"A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma","volume":"9","author":"Zhu","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"issue":"4770","key":"10.1016\/j.beha.2025.101628_bib14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.beha.2025.101628_bib15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"issue":"19","key":"10.1016\/j.beha.2025.101628_bib16","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101628_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.beha.2025.101628_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004749","article-title":"Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma","volume":"4","author":"Wallen","year":"2009","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.beha.2025.101628_bib19","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.2009.24.8153","article-title":"Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery","volume":"28","author":"Gunturu","year":"2010","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2025.101628_bib20","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1182\/blood.V126.23.4426.4426","article-title":"Cyclophosphamide and fludarabine conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy","volume":"126","author":"Bot","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2025.101628_bib21","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2025.101628_bib22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101628_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood-2021-150609","article-title":"Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in patients with relapsed\/refractory B-cell malignancies","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2025.101628_bib24","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.beha.2025.101628_bib25","article-title":"35MO Number of IL-2 doses and clinical outcomes of tumor-infiltrating lymphocyte (TIL) cell therapy: post hoc analysis of the C-144-01 trial of lifileucel in patients with advanced melanoma","volume":"16","author":"Hassel","year":"2022","journal-title":"Immuno-Oncol Technol"},{"issue":"12_Supplement","key":"10.1016\/j.beha.2025.101628_bib26","doi-asserted-by":"crossref","first-page":"PR018","DOI":"10.1158\/1535-7163.TARG-23-PR018","article-title":"Abstract PR018: IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors","volume":"22","author":"Wermke","year":"2023","journal-title":"Mol Cancer Therapeut"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101628_bib27","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood-2024-202090","article-title":"A phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory CD19 expressing hematologic malignancies (NCT05665062)","volume":"144","author":"Palomba","year":"2024","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2025.101628_bib28","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood.2024024952","article-title":"A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia","volume":"144","author":"Srinagesh","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101628_bib29","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1182\/blood-2022-159504","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/2159-8290.CD-NB2017-169","article-title":"JCAR015 in all: a root-cause investigation","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.beha.2025.101628_bib31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2025.101628_bib32","article-title":"CAR T cell therapy becomes CHIC: \"cytokine help intensified CAR\" T cells","volume":"13","author":"Thomas","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.beha.2025.101628_bib33","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/leu.2014.215","article-title":"IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia","volume":"29","author":"Pegram","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.beha.2025.101628_bib34","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.beha.2025.101628_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2020.06.089","article-title":"A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)","volume":"159","author":"O'Cearbhaill","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/jimmunol.1800033","article-title":"Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma","volume":"203","author":"Liu","year":"2019","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.beha.2025.101628_bib38","first-page":"e84","article-title":"TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv Gene Mol Cell Ther"},{"issue":"10","key":"10.1016\/j.beha.2025.101628_bib39","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib40","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1378842","article-title":"Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors","volume":"7","author":"Kunert","year":"2017","journal-title":"OncoImmunology"},{"issue":"13","key":"10.1016\/j.beha.2025.101628_bib41","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"issue":"16","key":"10.1016\/j.beha.2025.101628_bib42","article-title":"Safety and efficacy of armored huCART19-IL18 in patients with relapsed\/refractory lymphomas that progressed after anti-CD19 CAR T cells","volume":"42","author":"Svoboda","year":"2024","journal-title":"ASCO Annu Meet"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib43","doi-asserted-by":"crossref","DOI":"10.4110\/in.2024.24.e9","article-title":"Harnessing the power of IL-7 to boost T cell immunity in experimental and clinical immunotherapies","volume":"24","author":"Park","year":"2024","journal-title":"Immune Netw"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"48","key":"10.1016\/j.beha.2025.101628_bib45","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16_suppl","key":"10.1016\/j.beha.2025.101628_bib46","doi-asserted-by":"crossref","first-page":"9515","DOI":"10.1200\/JCO.2024.42.16_suppl.9515","article-title":"OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma","volume":"42","author":"Amaria","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2025.101628_bib47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nchembio.2565","article-title":"Rewiring T-cell responses to soluble factors with chimeric antigen receptors","volume":"14","author":"Chang","year":"2018","journal-title":"Nat Chem Biol"},{"issue":"2","key":"10.1016\/j.beha.2025.101628_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/btm2.10097","article-title":"TGF-\u03b2-responsive CAR-T cells promote anti-tumor immune function","volume":"3","author":"Hou","year":"2018","journal-title":"Bioeng Transl Med"},{"issue":"4","key":"10.1016\/j.beha.2025.101628_bib49","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.beha.2025.101628_bib50","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"issue":"17","key":"10.1016\/j.beha.2025.101628_bib51","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1182\/bloodadvances.2022008937","article-title":"Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome","volume":"7","author":"Bhaskar","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib52","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.beha.2025.101628_bib53","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41573-024-01100-5","article-title":"Novel strategies to manage CAR-T cell toxicity","volume":"24","author":"Mulvey","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.beha.2025.101628_bib54","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41591-018-0068-9","article-title":"Modeling cytokine release syndrome","volume":"24","author":"Rooney","year":"2018","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.beha.2025.101628_bib55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"10.1016\/j.beha.2025.101628_bib56","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.beha.2025.101628_bib57","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.beha.2025.101628_bib58","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"3\u20134","key":"10.1016\/j.beha.2025.101628_bib59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","volume":"46","author":"Hughes","year":"2024","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.beha.2025.101628_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.beha.2025.101628_bib61","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jtct.2024.08.018","article-title":"Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"10.1016\/j.beha.2025.101628_bib62","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101628_bib63","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1182\/blood-2024-205205","article-title":"Phase 2 trial of siltuximab for the treatment of cytokine release syndrome and immune effector cell associated neurotoxicity related to CAR-T cell therapy","volume":"144","author":"Narkhede","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2025.101628_bib64","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.beha.2025.101628_bib65","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/bloodadvances.2024015161","article-title":"Single-cell dynamics of breakthrough toxicities following anakinra prophylaxis for axicabtagene ciloleucel in lymphoma","volume":"9","author":"Frigault","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib66","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2025.101628_bib67","doi-asserted-by":"crossref","first-page":"10318","DOI":"10.1182\/blood-2022-167688","article-title":"ZUMA-19: a phase 1\/2 study of axicabtagene ciloleucel plus Lenzilumab in patients with relapsed or refractory large B-cell lymphoma","volume":"140","author":"Oluwole","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.beha.2025.101628_bib68","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024026586","article-title":"Itacitinib for the prevention of IEC therapy-associated CRS: results from the two-Part Phase 2 INCB 39110-211 study","author":"Frigault","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2025.101628_bib69","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14656566.2024.2340738","article-title":"Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy","volume":"25","author":"Walton","year":"2024","journal-title":"Expet Opin Pharmacother"},{"issue":"15","key":"10.1016\/j.beha.2025.101628_bib70","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2025.101628_bib71","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/bloodadvances.2022008697","article-title":"A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy","volume":"7","author":"Hirayama","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib72","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","article-title":"A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.beha.2025.101628_bib73","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.beha.2025.101628_bib74","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.beha.2025.101628_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.beha.2025.101628_bib76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692625000337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:05:00Z","timestamp":1753081500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692625000337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1521692625000337"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2025.101628","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokines and immune effector cell therapy","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2025.101628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101628"}}